Hikma Pharmaceuticals PLC (HKMPY)
Hikma Pharmaceuticals PLC operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in London, GL, GB. The stock last traded at $45.59, up 3.19% on the session, giving a market capitalisation of $4.76B. On trailing twelve-month figures it carries a trailing P/E of 12.41, a net margin of 11.3%. Its beta of 0.66 implies it has historically moved less than the broad market.
Hikma Pharmaceuticals PLC is a global pharmaceutical company that specializes in the development, production, commercialization, and distribution of a wide array of generic, branded, and in-licensed medicines. These pharmaceuticals are provided in various final dosage forms, including solid, semi-solid, liquid, and injectable formats. The company's business activities are organized into three core divisions: Injectables, Generics, and Branded products. The Injectables division primarily supplies generic injectable medications for hospital use. Its Generics segment focuses on offering oral and other non-injectable generic formulations to the retail market. The Branded segment, conversely, delivers branded generic drugs and products licensed from third parties to both retail consumers and hospitals. Hikma's product portfolio addresses numerous therapeutic areas, such as anti-infectives, cardiovascular health, central nervous system conditions, diabetes, oncology, pain management, and respiratory illnesses. The company maintains a substantial international footprint, operating throughout the United Kingdom, the United States, the Middle East, North Africa, Europe, and other global markets. Founded in 1978, Hikma Pharmaceuticals PLC has its headquarters in London, UK.
Hikma Pharmaceuticals PLC is most often compared with the following Healthcare names: